Menu
Search
|

Menu

Close
X

Biomarin Pharmaceutical Inc BMRN.OQ (NASDAQ Stock Exchange Global Select Market)

101.90 USD
-0.97 (-0.94%)
As of 4:00 PM EDT
chart
Previous Close 102.87
Open 103.01
Volume 479,461
3m Avg Volume 487,615
Today’s High 103.01
Today’s Low 101.33
52 Week High 104.42
52 Week Low 75.84
Shares Outstanding (mil) 176.71
Market Capitalization (mil) 18,146.69
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.76 Mean rating from 21 analysts

KEY STATS

Revenue (mm, USD)
FY18
373
FY17
1,314
FY16
1,117
FY15
890
EPS (USD)
FY18
-0.277
FY17
-0.429
FY16
-3.772
FY15
-1.079
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.05
Price to Sales (TTM)
vs sector
13.12
8.10
Price to Book (MRQ)
vs sector
6.47
4.20
Price to Cash Flow (TTM)
vs sector
--
22.23
Total Debt to Equity (MRQ)
vs sector
42.14
17.32
LT Debt to Equity (MRQ)
vs sector
29.13
13.18
Return on Investment (TTM)
vs sector
-2.89
13.17
Return on Equity (TTM)
vs sector
-3.85
15.10

EXECUTIVE LEADERSHIP

Jean-Jacques Bienaime
Chairman of the Board, Chief Executive Officer, Since 2015
Salary: $1,094,420.00
Bonus: --
Daniel Spiegelman
Chief Financial Officer, Executive Vice President, Since 2012
Salary: $559,231.00
Bonus: --
Henry Fuchs
President - Worldwide Research & Development, Since 2016
Salary: $637,231.00
Bonus: --
G. Eric Davis
Executive Vice President, General Counsel, Secretary, Since 2016
Salary: $409,593.00
Bonus: --
Jeff Ajer
Executive Vice President, Chief Commercial Officer, Since 2013
Salary: $524,231.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

105 Digital Dr
NOVATO   CA   94949-8703

Phone: +1415.5066700

BioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company's therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A). The Company is conducting clinical trials on various product candidates for the treatment of various diseases. Its clinical product candidates include Brineura, pegvaliase, vosoritide, BMN 270 and BMN 250.

SPONSORED STORIES